Risk–benefit profiles associated with receiving Moderna <scp>COVID</scp>‐19 (<scp>mRNA</scp>‐1273) vaccine as an additional pre‐booster dose in immune‐mediated dermatologic disease patients with low <scp>SARS‐CoV</scp>‐2‐specific immunity following the primary series: A prospective cohort study-Reference-Cited by-同舟云学术

Risk–benefit profiles associated with receiving Moderna COVID‐19 (mRNA‐1273) vaccine as an additional pre‐booster dose in immune‐mediated dermatologic disease patients with low SARS‐CoV‐2‐specific immunity following the primary series: A prospective cohort study

Published:2023-01-31 Issue:5 Volume:37 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Seree‐aphinan C.¹^ORCID,Suchonwanit P.¹^ORCID,Rattanakaemakorn P.¹^ORCID,Pomsoong C.¹,Ratanapokasatit Y.¹,Setthaudom C.²,Suangtamai T.³,Chanprapaph K.¹^ORCID,

Affiliation:

1. Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University Bangkok Thailand

2. Immunology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University Bangkok Thailand

3. Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital Bangkok Thailand

Funder

Mahidol University

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18890

Reference8 articles.

1. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review

2. Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis;Acta Dermato-Venereologica;2024-05-02

2. Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial;Vaccines;2024-01-11

3. Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients;Frontiers in Immunology;2023-03-15